The pharmaceutical powerhouse has two drugs that disrupt the transmission of the virus, one of which has been approved for ...
Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...
BofA raised the firm’s price target on Gilead (GILD) to $126 from $116 and keeps a Buy rating on the shares. For the last several weeks, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback